Published Online
on November 17, 2003

A more recent version of this article appeared on December 9, 2003

This Article Full Text (PDF) Data Supplement All Versions of this Article: 108/23/2926    most recent 01.CIR.0000101922.18151.7Bv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gaussin, V. Articles by Vatner, D. E. Search for Related Content PubMed PubMed Citation Articles by Gaussin, V. Articles by Vatner, D. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cardiomyopathy Heart Failure Hazardous Substances DB EPINEPHRINE Related Collections Genetically altered mice

Submitted on March 24, 2003
Revised on June 6, 2003
Accepted on August 12, 2003

Common Genomic Response in Different Mouse Models of -Adrenergic-Induced Cardiomyopathy

Vinciane Gaussin PhD, James E. Tomlinson PhD, Christophe Depre MD, PhD, Stefan Engelhardt MD, Christopher L. Antos PhD, Gen Takagi MD, PhD, Lutz Hein MD, James N. Topper MD, PhD, Stephen B. Liggett MD, Eric N. Olson PhD, Martin J. Lohse MD, Stephen F. Vatner MD^*, and Dorothy E. Vatner MD

From the University of Medicine and Dentistry of New Jersey and New Jersey Medical School (V.G., C.D., G.T., S.F.V., D.E.V.), Newark, NJ; Millennium Pharmaceuticals Inc (J.E.T., J.N.T.), South San Francisco, Calif; University of Wurzburg (S.E., L.H., M.J.L.), Wurzburg, Germany; UT Southwestern Medical Center (C.L.A., E.N.O.), Dallas, Tex; and University of Cincinnati Medical Center (S.B.L.), Cincinnati, Ohio.

^* To whom correspondence should be addressed. E-mail: vatnersf{at}umdnj.edu.

Background--Although -adrenergic receptor (AR) blockade therapy is beneficial in the treatment of heart failure, little is known regarding the transcriptional mechanisms underlying this salutary action.

Methods and Results--In the present study, we screened mice overexpressing Gs, ₁AR, ₂AR, or protein kinase A to test if a common genomic pathway exists in different models with enhanced -adrenergic signaling. In mice overexpressing Gs, differentially expressed genes were identified by mRNA profiling. In addition to well-known markers of cardiac hypertrophy (atrial natriuretic factor, CARP, and -myosin heavy chain), uncoupling protein 2 (UCP2), a protein involved in the control of mitochondrial membrane potential, and four-and-a-half LIM domain protein-1 (FHL1), a member of the LIM protein family, were predicted to be upregulated. Upregulation of these genes was confirmed by quantitative reverse transcriptase-polymerase chain reaction at all time points tested during the development of cardiomyopathy in mice overexpressing Gs. In mice overexpressing ₁AR, ₂AR, or protein kinase A, increased UCP2 and FHL1 expression was also observed at the onset of cardiomyopathy. AR blockade treatment reversed the cardiomyopathy and suppressed the increased expression of UCP2 and FHL1 in mice overexpressing Gs.

Conclusions--UCP2 and FHL1 are important candidate genes that correlate with the development of AR-induced cardiomyopathy in different mouse models with enhanced AR signaling. In addition to preserving cardiac function, AR blockade treatment also prevents the genomic regulation that correlates with the onset of heart failure.

Key words: receptors, adrenergic, beta • cardiomyopathy • genomics

This article has been cited by other articles:

				N. Hedhli and C. Depre Proteasome inhibitors and cardiac cell growth Cardiovasc Res, December 4, 2009; (2009) cvp226v3. [Abstract] [Full Text] [PDF]

				J. Naghshin, K. R. McGaffin, W. G. Witham, M. A. Mathier, L. C. Romano, S. H. Smith, A. M. Janczewski, J. A. Kirk, S. G. Shroff, and C. P. O'Donnell Chronic intermittent hypoxia increases left ventricular contractility in C57BL/6J mice J Appl Physiol, September 1, 2009; 107(3): 787 - 793. [Abstract] [Full Text] [PDF]

				G. Lewin, M. Matus, A. Basu, K. Frebel, S. P. Rohsbach, A. Safronenko, M. D. Seidl, F. Stumpel, I. Buchwalow, S. Konig, et al. Critical Role of Transcription Factor Cyclic AMP Response Element Modulator in {beta}1-Adrenoceptor-Mediated Cardiac Dysfunction Circulation, January 6, 2009; 119(1): 79 - 88. [Abstract] [Full Text] [PDF]

				I. Mikaelian, D. Coluccio, K. T. Morgan, T. Johnson, A. L. Ryan, E. Rasmussen, R. Nicklaus, C. Kanwal, H. Hilton, K. Frank, et al. Temporal Gene Expression Profiling Indicates Early Up-regulation of Interleukin-6 in Isoproterenol-induced Myocardial Necrosis in Rat Toxicol Pathol, February 1, 2008; 36(2): 256 - 264. [Abstract] [Full Text] [PDF]

				L. Pereira, M. Metrich, M. Fernandez-Velasco, A. Lucas, J. Leroy, R. Perrier, E. Morel, R. Fischmeister, S. Richard, J.-P. Benitah, et al. The cAMP binding protein Epac modulates Ca2+ sparks by a Ca2+/calmodulin kinase signalling pathway in rat cardiac myocytes J. Physiol., September 1, 2007; 583(2): 685 - 694. [Abstract] [Full Text] [PDF]

				N. Bodyak, D. L. Rigor, Y.-S. Chen, Y. Han, E. Bisping, W. T. Pu, and P. M. Kang Uncoupling protein 2 modulates cell viability in adult rat cardiomyocytes Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H829 - H835. [Abstract] [Full Text] [PDF]

				G. W. Dorn II The Fuzzy Logic of Physiological Cardiac Hypertrophy Hypertension, May 1, 2007; 49(5): 962 - 970. [Full Text] [PDF]

				M. J. McGrath, D. L. Cottle, M.-A. Nguyen, J. M. Dyson, I. D. Coghill, P. A. Robinson, M. Holdsworth, B. S. Cowling, E. C. Hardeman, C. A. Mitchell, et al. Four and a Half LIM Protein 1 Binds Myosin-binding Protein C and Regulates Myosin Filament Formation and Sarcomere Assembly J. Biol. Chem., March 17, 2006; 281(11): 7666 - 7683. [Abstract] [Full Text] [PDF]

				J. Wallis, C. A. Lygate, A. Fischer, M. ten Hove, J. E. Schneider, L. Sebag-Montefiore, D. Dawson, K. Hulbert, W. Zhang, M. H. Zhang, et al. Supranormal Myocardial Creatine and Phosphocreatine Concentrations Lead to Cardiac Hypertrophy and Heart Failure: Insights From Creatine Transporter-Overexpressing Transgenic Mice Circulation, November 15, 2005; 112(20): 3131 - 3139. [Abstract] [Full Text] [PDF]

				D. E. Montgomery, V. L. M. Rundell, P. H. Goldspink, D. Urboniene, D. L. Geenen, P. P. de Tombe, and P. M. Buttrick Protein kinase C{varepsilon} induces systolic cardiac failure marked by exhausted inotropic reserve and intact Frank-Starling mechanism Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1881 - H1888. [Abstract] [Full Text] [PDF]

				M. ten Hove, C. A. Lygate, A. Fischer, J. E. Schneider, A. E. Sang, K. Hulbert, L. Sebag-Montefiore, H. Watkins, K. Clarke, D. Isbrandt, et al. Reduced Inotropic Reserve and Increased Susceptibility to Cardiac Ischemia/Reperfusion Injury in Phosphocreatine-Deficient Guanidinoacetate-N-Methyltransferase-Knockout Mice Circulation, May 17, 2005; 111(19): 2477 - 2485. [Abstract] [Full Text] [PDF]